• 한국임상수의학회지
• /
• 제13권1호
• /
• pp.81-86
• /
• 1996

Systemic lupus erythematosus in a dog, suspected systemic lupus erythematosus in a dog, and autoimmune thrombocytopenic purpura hemmorrhagica in a dog are reported. A fice-year old, female Chihuahua (Case 1) showed initially hemorrhagic diathesis and purpura hemorrhagica. Afterward, it showed polymyositis and polyarthritis. LE-cell was demonstrated on LE-cell preparation trom blood. Systemic lupus erythematosus was diagnosed. This reponded well to the immunosuppressants, but developed iatrogenic Cushing syndrome and steroid hepatopathy. A two-and-half-year old, male toy poodle (Case 2) had chief complaint of red urine. Occult blood test for the urine sediment. This did not respond at all to antibiotics and carbazochrome, which is one of systemic coagulants. LE-cell was demonstrated on LE-cell preparation from blood. This responded relatively well to immunosupressants such as prenisolone, azathioprine and cyclophosphamide. systemic lupus erythematosus is suspected. A nine-year-and-three-month old, female Maltese (Case 3), which had history of congestive heart failure and ovariohysterectomy showed purpura hemorrhagica in the skin of chest. This had severe thrombocytopenia and leukocytosis. As prednisolone was administered before immunological examination or demonstration of LE-cell, it was impossible to diagnose whether purpura hemorrhagica developed as a member of systemic lupus erythematosus or independent of systemic lupus erythematosus. This responded well to prednisolone, and so autoimmune thrombocytopenic purpura hemorrhagica was diagnosed.

• Maxillofacial Plastic and Reconstructive Surgery
• /
• 제20권2호
• /
• pp.97-100
• /
• 1998

Systemic lupus erythematosus is a severe cutaneous-systemic disorder of unknown etiology, It is represented with erythematous patches on the face in a so-called butterfly distribution, and characteristically classified as an autoimmune disease with antinuclear antibodies. The autoimmune diseases such as systemic lupus erythematosus, $Sj{\ddot{o}}gren$ syndrome, rheumatoid arthritis have been associated with lymphoid malignancy - leukemia, malignant lymphoma - which could involve various organs(spleen, liver, brain, mediastinal lymph node, supraclavicular lymph node, inguinal lymph node, cervical lymph node etc.). Many authors have studied about the association of systemic lupus erythematosus and malignant lymphoma, but exact etiology is still unknown. A common viral etioloty for systemic lupus erythematosus has been suggested since virus-like particles have been found in the glomerular endothelium of patients with systemic lupus erythematosus. These oncogenic viruses may be responsible for the higher frequency of malignant lymphoma in patients with systemic lupus erythematosus. In the other theory, the causes of malignant lymphoma are the defect of immune system due to systemic lupus erythematosus and the long-term use of therapeutics for treatment of systemic lupus erythematosus. When the cellular immune system(delayed hypersensitivity) is impaired by immunosuppressive drugs, it is likely that the body is no longer able to recognize and reject malignant cells as they arise; they continue to grow and divide unhindered. The impairment of the cellular immune system may allow growth of oncogenic virus or the survival of neoplatic tissues. 47-year old female patient treated systemic lupus erythematosus with steroid and immunosuppressive drugs for 5 years visited to our hospital due to elevated mass on left upper anterior maxilla area. By performing biopsy, we diagnosed this lesion as malignant lymphoma and referred to oncologist for chemotherapy. So we report a case of malignant lymphoma due to systemic lupus erythematosus with review of literatures.

• 한국임상약학회지
• /
• 제21권3호
• /
• pp.276-279
• /
• 2011

We report an unusual case of lupus flare induced by intravenous vancomycin in a patient with systemic lupus erythematosus. Due to methicillin resistant staphylococcus aureus in wound culture, intravenous vancomycin was administered to the patient. The patient had been on vancomycin for several days then she experienced fever, malar rash, and vomiting. Based on laboratory results, it was confirmed as lupus flare. Oral prednisolone was given to the patient for symptom control. However, when vancomycin was readministered, the patient had similar symptom to the previous one more intensively. Vancomycin was stopped then the patient became stable. This case report demonstrates that intravenous vancomycin may manifest as lupus flare in patients with systemic lupus erythematosus.

• 대한피부과학회지
• /
• 제56권10호
• /
• pp.620-623
• /
• 2018

Vitiligo is a multifactorial disorder. Neural, biochemical, and autoimmune mechanisms have been hypothetically suggested as etiopathological contributors to this condition. Autoimmunity focuses primarily on genetic factors and the association between vitiligo and other autoimmune disorders including autoimmune thyroid disease, rheumatoid arthritis, psoriasis, type 1 diabetes, pernicious anemia, and Addison's disease. We describe a 35-year-old man with systemic lupus erythematosus who developed concurrent vitiligo and discoid lupus erythematosus suggesting the possible autoimmune association between these 2 different diseases.

• Annals of Clinical Neurophysiology
• /
• 제9권1호
• /
• pp.29-32
• /
• 2007

Recurrent transverse myelitis is a rare manifestation of systemic lupus erythematosus. Recurrent transverse myelitis presents the biggest diagnostic problem, since it is common manifestation of multiple sclerosis. But it can also be the only feature or first manifestation in systemic lupus erythematosus. Neurological manifestations and magnetic resonance imaging can be indistinguishable, and there are no specific diagnostic tools. Here we describe a 59-year-old female having a systemic lupus erythematosus with recurrent transverse myeltitis. No uniform therapeutic protocol exists for systemic lupus erythematous with transverse myelitis, and the prognosis is usually poor. We suggest that aggressive treatment (usually with pulses of methylprednisolone and cyclophosphamide) might improve the prognosis of systemic lupus erythematosus with transverse myeltis.

• 근관절건강학회지
• /
• 제24권3호
• /
• pp.196-204
• /
• 2017

Purpose: This study was conducted to explore the mediating effect of resilience in the relationship between stress and therapeutic compliance in patients with systemic lupus erythematosus. Methods: The subject (N=145) was a systemic lupus erythematosus patient who visited the D Hospital in B city. Data collection was conducted from January 2016 to August 2016. Twenty-five resilience measurement tools, 20 stress measurement tools, 39 therapeutic compliance measurement tools used to measure resilience, stress and therapeutic compliance levels. The collected data were analyzed using descriptive analysis, Pearson correlation, 3-step regression analysis of Baron and Kenny, and Sobel test in SPSS/WIN 21.0. Results: There was a significant negative correlation between stress and therapeutic compliance, a significant negative correlation between stress and resilience, and significant positive correlation between resilience and therapeutic compliance. Resilience showed a direct effect on therapeutic compliance through stress as a mediating variable. Conclusion: It is necessary to develop appropriate resilience enhancement program to improve therapeutic compliance with systemic lupus erythematosus.

• 디지털융복합연구
• /
• 제19권11호
• /
• pp.615-623
• /
• 2021

본 연구는 루푸스 환자의 극복력에 영향을 미치는 요인을 파악하기 위해 수행되었다. 연구대상자(N=118)는 D시 소재의 E병원을 내원한 루푸스 환자를 대상으로 하였다. 수집된 자료는 기술통계, t-tset, ANOVA, pearson correlation, multiple regression으로 분석하였다. 연구결과, 극복력에 영향을 미치는 요인은 불확실성의 질병의 영향 영역, 피로, 불확실성의 자기관리 영역과 의사에 대한 신뢰영역 이었다. 본 연구를 토대로 루푸스 환자의 극복력을 향상시키기 위해서는 환자가 인지하는 불확실성을 줄이고 피로 조절을 위한 다각적인 접근이 필요하다. 또한 영향요인을 반영한 루푸스 환자의 극복력 증진을 위한 효과적인 간호중재 프로그램의 개발이 요구된다.

• 대한수의학회지
• /
• 제56권1호
• /
• pp.47-49
• /
• 2016

An 11-year-old, spayed female poodle presented with fever and shifting lameness. Physical examination revealed hyperthermia ($40.6^{\circ}C$), and proteinuria was detected upon urinalysis. Increased neutrophils (83%) and decreased viscosity were revealed upon synovial fluid analysis. Serum antinuclear antibody was positive at 1 : 80. Based on these findings, the dog was diagnosed with systemic lupus erythematosus. Immunosuppressive therapy was initiated with prednisolone and cyclosporine, and the condition was markedly improved after the treatments. This case report describes the clinical and laboratory findings, imaging characteristics and successful outcomes after prednisolone plus cyclosporine therapy in a canine systemic lupus erythematosus case.

• Neonatal Medicine
• /
• 제18권2호
• /
• pp.391-394
• /
• 2011

저자들은 다형 홍반과 구강 궤양으로 발현하였고 빈혈, 혈소판 감소증, 간기능 이상 등을 동반한 신생아 루푸스 환아의 확진과 신생아 진단을 통하여 무증상 산모 루푸스를 역으로 진단한 1례를 경험하였기에 문헌 고찰과 함께 보고하는 바이다.

• 대한약침학회지
• /
• 제3권2호
• /
• pp.245-255
• /
• 2000

After observing a patient diagnosed with Systemic Lupus Erythematosus from the September 21, 2000 to the January 13, 2001, the following results are obtained. Method and Result: We treated one case of Systemic Lupus Erythematosus with the Korean Bee Venom Therapy and the other Oriental Medical treatments. In acupuncture therapy, Korean Bee-venom Therapy is believed to be outstanding way to treat Systemic Lupus Erythematosus. Korean Bee Venom Therapy is treated on the following acupuncture points: ST36(B23(Shinsu:腎兪), BL26(Guanyuanshu:關元兪), ST36(Chok-Samni:足三里), LI4(Hapkok:合谷), LV3(Taechung), SP10(Hyolhae:血海) SP6 (Samumgyo;三陰交). In addition, CFC(Carthami Flos;紅花 and Cervi Pantotrichum Cornu;) Herbal-Acupuncture was applied on the acupucture points of GB20(Pungji: 風池), GB21(Kyonjong:), as well as BUM(It was made of Boviscalculus(牛黃), Moschus and Fel ursi Herbal-Acupuncture was given on CV17(Chonjung). In herbal medication, based on the Sasang Constitution, Taeyumin Chungsimyunja-Tang was given to the patient. As the results of these treatments, general conditions of this patient improved drastically. Conclusion: Based on the clinical results, traditional Korean Medical treatment is believed to be effective for treating Systemic Lupus Erythematosus, and futher studies should be carried out to provide more valuable information.